Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05130177

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase II Study of PD-1 Inhibitor Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Sponsor: Arcus Biosciences, Inc.

Conditions Melanoma

Interventions Domvanalimab Zimberelimab

Updated 8 times since 2021 Last updated: May 2, 2025 Started: Mar 16, 2022 Primary completion: Jan 31, 2028 Completion: Jan 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Melanoma and is currently actively recruiting participants. Arcus Biosciences, Inc. leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
May 2023 — Jun 2024 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

May 2022 — May 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE2
Dec 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arcus Biosciences, Inc.
Diwakar Davar

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States